AOD-9604 vs MOTS-c

The Dose Guy’s verdict

Oct 27, 2026
6 sources

Neither one is a fat-loss drug, and if fat on the scale is the goal, run retatrutide or tirzepatide instead. Between these two, MOTS-c, as a short experiment for holding energy up in a deficit. AOD-9604 went to human trials for obesity and came back with nothing worth publishing; MOTS-c has never been tested in a person at all. An open question beats a closed one.

Which would I take?MOTS-c, as an experiment. AOD-9604, never.

How they differ

Both get sold as fat-loss peptides, and both rest on rodents, but their human stories point opposite ways. AOD-9604 is a tail fragment of growth hormone, built to keep its fat-burning effect without the growth. It worked in obese rats and mice, went into human obesity trials in the early 2000s, and the developer walked away without publishing results. That silence is the answer. MOTS-c is a signal your own mitochondria make when energy runs short; it kept mice lean and old mice running, and nobody has run the human trial yet. One is a known failure, the other an open question.

So the pick is MOTS-c, for the job it might actually do: holding energy up through a calorie deficit and around fasted cardio. Do not expect the scale to move on it. If the scale is the point, retatrutide for a big cut, or tirzepatide if you are already lean.

In practice, AOD-9604 is a small daily pin on an empty stomach, and MOTS-c is a bigger dose a few times a week, timed to training. That makes MOTS-c the easier experiment to judge: within a few weeks you know whether your sessions feel different.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

Neither has a published human result. AOD-9604’s absence is a failed trial program; MOTS-c’s is a trial nobody has run:

In obese Zucker rats, oral AOD-9604 at 500 micrograms per kg daily for 19 days reduced weight gain by more than 50%, 15.8 g versus 35.6 g in controls.Horm Res 2000 · rat study

By February 2002, AOD-9604 was in phase 2a trials as a potential obesity treatment.2004 · development review

MOTS-c treatment in mice prevented diet-induced obesity, along with the insulin resistance that comes with age and a high-fat diet.Cell Metab 2015 · discovery · mouse

In adipose-derived stromal cells from six donors with obesity, exogenous MOTS-c reduced proliferation and increased p16, p21, and TNF-alpha expression, markers of cells heading into senescence. A dish, not a person.Inflamm Regen 2026 · in vitro

No published randomized human efficacy results exist for AOD-9604 in obesity, no controlled human trial has tested injected MOTS-c, and no trial has compared the two.as of Aug 2026

The rodent results look alike on paper. Only one of these has already been tested in people and come up empty.

How people run them

I am not writing a protocol for AOD-9604. Its developer abandoned it after the human data came in. For the record, the vendor-market protocol is 250 to 300 mcg sub-q daily on an empty stomach for 8 to 12 weeks, built by sellers, not by anyone who saw the trial data. If you are on it now, stop; there is nothing to taper.

MOTS-c has no studied human dose either. The community runs 5 to 10 mg sub-q two to four times a week, often before fasted training, and that is forum consensus, not a result. If you run it, go low, go short, and log how training feels. If nothing shifts in the first few weeks, it is not coming at that dose.

Do not stack the two. With two unknowns in you, when something feels off, or something works, you cannot tell which one did it. If you want real fat loss alongside the MOTS-c experiment, the partner is a gut-hormone drug like retatrutide, not AOD-9604.

Side effects, side by side

Neither has published human safety data, so this is user reports and gaps:

anecdotalInjection-site irritation on both. Mild water retention and the odd headache on AOD-9604, all from user reports with no controlled denominator.

monitorBlood sugar. AOD-9604 was built to dodge growth hormone’s blood-sugar hit, and the rodents showed none. MOTS-c works the same energy sensor metformin does, so notice how fasted sessions feel.

unknownThe MOTS-c cell study pushed fat-tissue cells toward senescence. A dish, not a person, but reason enough to keep courses short.

unknownNo human safety data has been published for either. With AOD-9604, the silence after real trials leaves you guessing whether the problem was efficacy, safety, or both.